Transaction DateRecipientSharesTypePriceValue
9th February 2021Capital Management, L.P. Ra2,848,596Open or private purchase$18.00$51,274,728.00
9th February 2021Capital Management, L.P. Ra1,664,549Conversion of derivative$0.00
9th February 2021Capital Management, L.P. Ra280,330Conversion of derivative$0.00
9th February 2021Capital Management, L.P. Ra130,970Open or private purchase$18.00$2,357,460.00
9th February 2021Capital Management, L.P. Ra3,784,120Conversion of derivative$0.00
9th February 2021Capital Management, L.P. Ra1,414,026Conversion of derivative$0.00
4th February 2021Capital Management, L.P. Ra11,651,597Conversion of derivative$0.00
6th January 2021Frank Neumann150,000Grant/award etc.$0.00
18th December 2020Dan Paterson135,851Grant/award etc.$0.00
18th December 2020Brian M Stuglik203,776Grant/award etc.$0.00
Verastem
Verastem logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Verastem, Inc. is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K)


Ticker: VSTM
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1526119
Employees: 169
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $125 M (0%)
Inventory, Net: $6 M (0%)
Assets, Current: $145 M (70%)
Property, Plant and Equipment, Net: $791 Th (-16%)
Other Assets, Noncurrent: $401 Th (-50%)
Assets: $199 M (36%)
Accounts Payable, Current: $2 M (-76%)
Accrued Liabilities, Current: $21 M (0%)
Liabilities, Current: $29 M (-3%)
Other Liabilities, Noncurrent: $870 Th (0%)
Liabilities: $84 M (-38%)
Common Stock, Value, Issued: $17 Th (112%)
Common Stock, Shares, Issued: $169 M (211260%)
Additional Paid in Capital, Common Stock: $700 M (31%)
Retained Earnings (Accumulated Deficit): $586 M (0%)
Stockholders' Equity (Parent): $114 M (0%)
Liabilities and Equity: $199 M (36%)
Revenue: $4 M (-53%)
Research and Development: $9 M (-53%)
Operating Income/Loss: $21 M (-55%)